Bibliography
- Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-35
- Martínez F, Avecilla A. Combined hormonal contraception and venous thromboembolism. Eur J Contracept Health Care 2007;12:97-106
- Kaper RF, Norpoth T, Rekers H. Third- and second-generation oral contraceptives are associated with similar risk estimates for venous thromboembolism. Eur J Contracept Reprod Health Care 2000;5:1-15
- Conard J. Biological coagulation findings in third-generation oral contraceptives. Hum Reprod Update 1999;5:672-80
- Aldrighi JM, De Campos LS, Eluf Gebara OC, et al. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters. Gynecol Endocrinol 2006;22:1-4
- Blickstein D, Blickstein I. Oral contraception and thrombophilia. Curr Opin Obstet Gynecol 2007;19:370-6
- Legnani C, Cosmi B, Valdre L, et al. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 2003;1:112-7
- Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med 2001;1:7-26
- World Health Organization. Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization; 1996
- HFA. European Health for All database (online database). Copenhagen, WHO Regional Office for Europe, 2006. Available from: http://data.euro.who.int/hfadb/ [Last accessed May 2008]
- Plu-Bureau G, Scarabin PY, Bara L, et al. Factor VII activation and oral contraceptives. Thromb Res 1993;70:275-80
- Herkert O, Kuhl H, Sandow J, et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of the glucocorticoid receptor. Circulation 2001;104:2826-31
- Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997;78:315-26
- Ferreira AC, Montes MB, Franceschini SA, et al. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women. Int J Fertil Womens Med 2001;46:265-70
- Ferreira AC, Montes MB, Franceschini SA, et al. Third-generation progestogen type influences hemostatic changes caused by oral contraceptives in Brazilian women. Contraception 2001;64:353-6
- Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 2003;67:173-85
- Wiegratz I, Lee JH, Kutschera E, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception 2004;70:97-106
- Prasard RNV, Koh SCL, et al. Effects on haemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel. Clin Appl Throm Haemost 1999;5:60-70
- Machado RB, Fabrini P, Cruz AM, et al. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 2004;70:365-70
- Winkler UH, Schindler AE, Endrikat J, et al. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol. Contraception 1996;53:75-84
- Tchaikovski SN, van Vliet HA, Thomassen MC, et al. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007;98:1350-6
- van Vliet HA, Bertina RM, Dahm AE, et al. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008;6:346-51
- Creatsas G, Kontopoulou-Griva I, Deligeoroglou E, et al. Effects of two combined monophasic and triphasic ethynilestradiol/gestodene oral contraceptives on natural inhibitors and other hemostatic variables. Eur J Contracept Reprod Health Care 1997;2:31-8
- Lippi G, Manzato F, Brocco G, et al. Prothrombotic effects and clinical implications of third-generation oral contraceptives use. Blood Coagul Fibrinolysis 2002;13:69-72
- Meijers JC, Middeldorp S, Tekelenburg W, et al. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent downregulation of fibrinolysis: a randomized crossover study of two low-dose oral contraceptives. Thromb Haemost 2000;84:9-14
- Zahn CM, Gonzalez DI Jr, Suto C, et al. Low-dose oral contraceptive effects on thromboelastogram criteria and relationship to hypercoagulability. Am J Obstet Gynecol 2003;189:43-7